socks4 proxy 50: Résultats de recherche pour Hunter

Affichage des articles triés par pertinence pour la requête Hunter. Trier par date Afficher tous les articles

mercredi 27 janvier 2016

Hunter Zolomon

Share This: Facebook Twitter Google+ Stumble Digg

samedi 30 janvier 2016

Martin_Shkreli
Martin_Shkreli
Martin_Shkreli 2016-01-30
Martin_Shkreli 2016
Read more about Martin_Shkreli viste out website : http://www.startdays.com
All about ==> Martin_Shkreli viste out website : http://www.startdays.com
Martin_Shkreli update 2016-01-30 http://www.startdays.com
http://www.startdays.com
Martin Shkreli (born 1983) is an American entrepreneur and financial and pharmaceutical executive. He is co-founder of the hedge fund MSMB Capital Management, co-founder and former chief executive officer (CEO) of the biotechnology firm Retrophin LLC, and founder and former CEO of Turing Pharmaceuticals AG. In September 2015, Shkreli received widespread criticism when Turing obtained the manufacturing license for the antiparasitic drug Daraprim and raised its price by 5,556 percent (from US$13.50 to US$750 per tablet).
On December 17, 2015, Shkreli was arrested by the FBI on charges of securities fraud and released on bail. He resigned as CEO of Turing Pharmaceuticals and was replaced by the company's board chairman, Ron Tilles.

Early life and education
Martin Shkreli was born April 1, 1983, the son of Albanian and Croatian immigrants who worked as janitors. He, his two sisters, and his brother grew up in a working class community in Sheepshead Bay, Brooklyn.
Shkreli attended Hunter College High School. Shkreli eventually stopped attending classes and was asked to leave the school before his senior year, but received the credits necessary for his diploma through a program that placed him in an internship at the Wall Street hedge fund Cramer, Berkowitz and Company when he was 17. Sources are conflicted on whether Shkreli graduated from Hunter or whether he received sufficient credits there but actually graduated from City-As-School High School.
He went on to receive a bachelor's degree in business administration from New York's Baruch College in 2005. Shkreli told Vanity Fair that he developed an interest in chemistry when a family member suffered from treatment-resistant depression. In March 2015, Hunter College announced that Shkreli had donated $1,000,000 dollars to Hunter College High School. According to The New York Times, "At the time, Hunter officials hailed the gift, with the alumni associationâ€™s website declaring 'Martin Shkreli, from the Class of 2001, donates $1,000,000 to HCHS!' When asked this week whether Hunter was considering returning the money, a press officer declined to comment. Two members of the alumni association did not respond to emails. Several classmates say that when they heard about Mr. Shkreliâ€™s gift, they could not help but wonder whether it was meant as a sly act of one-upmanship." One of the classmates told The Times: â€œI thought it was weird since he hadn't graduated. It seemed almost
like a 'take that' move.â€

Career
During Shkreli's time at Cramer, Berkowitz and Company, he recommended short-selling (shorting) a biotech stock, believing that the companyâ€™s share price would drop. When it did so, Cramer's hedge fund profited. In 2003, Regeneron Pharmaceuticals was testing a weight loss drug, and Shkreli, at age 19, predicted that the stock price would fall. Shkreli's prediction drew the attention of the Securities and Exchange Commission, which investigated Shkreli's knowledge about the stock but found no wrongdoing on his part.

Hedge funds founded
After four years as an associate at Cramer Berkowitz, Shkreli worked as an analyst for Intrepid Capital Management and UBS Wealth Management. He then started his first hedge fund, Elea Capital Management, in 2006. In October 2007, Lehman Brothers won a $2.3 million default judgment against Shkreli and Elea, but collapsed before it could collect on the ruling.
In September 2009, Shkreli launched MSMB Capital Management, which took its name from the initials of the two founding portfolio managers, Shkreli and his childhood friend Marek Biestek. Shkreli and Biestek shorted biotech companies, then described flaws in the companies on stock trading chat rooms. Shkreli wrote on one investment site, â€œClinical data can be misleading, innocently biased, meaningless, manipulated and sometimes even downright doctored.â€
MSMB traded Orexigen Therapeutics stock in February 2011, around the time that its price plunged when the Food and Drug Administration (FDA) declined to approve the drug Contrave.
In 2011, Shkreli filed requests with the FDA to reject a new cancer diagnostic device from Navidea Biopharmaceuticals and an inhalable insulin therapy from MannKind Corporation while publicly short-selling both companies' stocks, the values of which dropped after Shkreli's interventions. The companies had difficulty launching the products as a result, although the FDA ultimately approved both.

Retrophin
Shkreli founded Retrophin Inc. (NASDAQ: RTRX â€" the name is a portmanteau of "recombinant dystrophin") in 2011, and ran it as a portfolio company with an emphasis on biotechnology, to create treatments for rare diseases.
In 2011, MSMB made an unsolicited bid for AMAG Pharmaceuticals, US$378 million, and in September 2014, it acquired the rights to Thiola, a drug used to treat the rare disease cystinuria.
Retrophin's board decided to replace Shkreli in September 2014, and he resigned from the company the following month. He was replaced by Stephen Aselage. During Shkreli's tenure as CEO, the company's employees used alias Twitter accounts to make gangster rap jokes and encourage short selling of other biotech stocks. Critics argued that Shkreli was intelligent but too immature and unfocused for the job of CEO.
After Shkreli's departure, Retrophin filed a US$65 million lawsuit against him in August 2015, claiming that he had breached his duty of loyalty to the biopharmaceutical company in a long-running dispute over his use of company funds and "committed stock-trading irregularities and other violations of securities rules." The lawsuit alleged that Shkreli had threatened and harassed a former MSMB employee and his family. Shkreli and some of his business associates have been under criminal investigation by the U.S. Attorney for the Eastern District of New York since January 2015. Shkreli invoked his Fifth Amendment right against self-incrimination in order to avoid testifying during civil depositions.
Shkreli's name is on two patents held by Retrophin for drugs to treat PKAN.

Turing Pharmaceuticals
Shkreli founded Turing Pharmaceuticals in February 2015, after his departure from Retrophin. He launched Turing with three drugs in development acquired from Retrophin: an intranasal version of ketamine for depression, an intranasal version of oxytocin, and Vecamyl for hypertension. Shkreli set a business strategy for Turing: to obtain licenses on out-of-patent medicines and reevaluate the pricing of each in pursuit of windfall profits for the new company, without the need to develop and bring its own drugs to market. As markets for out-of-patent drugs are often small, and obtaining regulatory approval to manufacture a generic version is expensive, Turing calculated that with closed distribution for the product and no competition, it could set high prices.

Price hike controversy
In accordance with Shkreli's business plan, Turing acquired Daraprim (pyrimethamine) â€" an FDA-approved therapeutic since 1953 â€" for US$55 million on August 10, 2015, from Impax Laboratories.) The drug's most prominent use as of late 2015 was as an anti-malarial and an antiparasitic, in conjunction with leucovorin and a sulfonamide, to treat patients with toxoplasmosis, including in AIDS populations. The patent for Daraprim expired in 1953, and no generic version was available. The Turing-Impax deal included the condition that Impax remove the drug from regular wholesalers and pharmacies, so in June 2015, two months before the sale to Turing was announced, Impax switched to tightly controlled distribution. In keeping with its strategy for pricing in the face of limited competition (see above), Turing maintained the closed distribution.
On September 17, 2015, Dave Muoio of Healio, an in-depth clinical information website for health care specialists, reported on a letter from the Infectious Diseases Society of America and the HIV Medicine Association to executives at Turing, questioning a new pricing for Daraprim. The price of a dose of the drug in the U.S. market increased from US$13.50 to US$750 per pill, overnight, a 5451% increase.
The price increase was initially criticized, jointly, by the Infectious Diseases Society of America and the HIV Medicine Association, by the Pharmaceutical Research and Manufacturers of America, and soon thereafter by presidential candidates Hillary Clinton, Bernie Sanders, and Donald Trump. A subsequent organized effort called on Turing to return pricing to pre-September levels and to address several matters relating to the needs of patients, an effort that garnered endorsements from more than 160 medical specialty and patient-related organizations (as of early December 2015, 164 organizations from 31 states, the District of Columbia, and Puerto Rico).
In response to the controversy, the record label Collect Records publicly ended its business relationship with Shkreli, who had invested in the company.
In an interview with Bloomberg Markets, Shkreli claimed that despite the price increase, patient co-pays would actually be lower; that many patients would get the drug at no cost; that Turing has expanded its free drug program; and that it sold half of its drugs for one dollar. He defended the price hike by saying, "If there was a company that was selling an Aston Martin at the price of a bicycle, and we buy that company and we ask to charge Toyota prices, I don't think that that should be a crime." A few days later, Shkreli announced that he planned to lower the price by an unspecified amount, "in response to the anger that was felt by people." But in late November, Turing reversed course and said it would not lower the price after all. Following a request by Senator Bernie Sanders and Representative Elijah Cummings for details of Turing Pharmaceuticals' finances and price-setting practices in September 2015, the company hired four lobbyists from Buchanan, Ingersoll & Rooney with ba
ckgrounds in health care legislation and pharmaceutical pricing. In addition to the lobbyists, Shkreli hired a crisis public relations firm to help explain the pricing decision.
On October 22, 2015, Mark Baum, CEO of Imprimis Pharmaceuticals, announced that his company would provide a compounded (co-formulated) form of pyrimethamine, Daraprim's active agent, containing leucovorin, one of two drugs (alongside a sulfonamide) in the standard protocol to treat toxoplasmosis in AIDS and other populations.
Baum noted, "This is not the first time a sole supply generic drug â€" especially one that has been approved for use as long as Daraprim â€" has had its price increased suddenly and to a level that may make it unaffordable." He announced the availability of the compounded replacement for Daraprim as a part of a larger corporate program, "Imprimis Cares," to make "novel and customizable medicines available to physicians and patients... at accessible prices." Imprimis is now offering its compounded, orally taken formulations of pyrimethamine and leucovorin beginning at US$99 for a 100-count bottle, essentially a dollar a dose.
On November 23, 2015, Turing announced that the company would not reduce the list price of Daraprim, but said it planned instead to negotiate volume discounts of up to 50% for hospitals. Turing said it was not as important to cut the list price as to reduce the cost to hospitals, where most patients get their initial treatment. The company pledged that no patient needing Daraprim would ever be denied access. Infectious disease specialists and patient advocates, including Tim Horn of the Treatment Action Group and Carlos del Rio of the HIV Medicine Association, said Turing's actions were insufficient, given that patients initially treated for days at a hospital typically have to continue the treatment for weeks or months after leaving.

KaloBios Pharmaceuticals
In November 2015, an investor group led by Shkreli acquired a majority stake in KaloBios Pharmaceuticals, Inc. (NASDAQ: KBIO), a biopharmaceutical company based in South San Francisco, California. Shkreli was named CEO of the company and also planned to continue in the role of CEO of Turing Pharmaceuticals. After his December 2015 arrest, KaloBios Pharmaceuticals terminated him as CEO. On 29 December KaloBios filed for Chapter 11 bankruptcy. This followed NASDAQ delistng its shares, and the resignation of two directors.

Arrest
On December 17, 2015, Shkreli was arrested following a federal indictment by the FBI on securities fraud charges after an investigation into his tenure at MSMB Capital Management and Retrophin. He was accused of running a Ponzi-like scheme. A United States Department of Justice press release said, "As alleged, Martin Shkreli engaged in multiple schemes to ensnare investors through a web of lies and deceit." In an interview with the Wall Street Journal, Shkreli claimed that he was targeted by law enforcement for his price hikes of the drug Daraprim and his flamboyant personality. In his nationally syndicated column, political commentator Robert Reich suggested that what Shkreli "did wrong" was being more audacious while "playing the same game many others are playing on Wall Street".

Other projects
Shkreli is a League of Legends player who goes by the name "Imagine Cerebral" and began expressing interest in purchasing an eSports team in 2014. In May, Enemy eSports announced that it had rejected a US$1.2 million offer from Shkreli. Eventually, he founded his own team, Odyssey eSports, and aimed to qualify for the 2015 North American League of Legends Challenger Series. The team lost to Cloud9 Tempest in the qualifying tournament and failed to qualify. In August, Odyssey merged with Imagine, with Shkreli becoming chairman of the team. During the merger, the team acquired the Dota 2 team Leviathan.
In November 2015, Shkreli began livestreaming on YouTube showing him playing games such as League of Legends and chess, as well as offering financial advice. Shkreli had previously streamed on the website Twitch but switched to YouTube after his account was banned from Twitch for unknown reasons. Shkreli received a phone call from the FBI on the day of his arrest live while streaming. When Shkreli was arraigned in December and released on bail, he continued streaming from his apartment.
Shkreli had a contract with Collect Records and has offered to bail out Bobby Shmurda.

Personal life

---------------------------------------
------ GOOGLE SEARCH ABOUT Martin_Shkreli UPDATE 2016-01-30
---------------------------------------

http://www.startdays.com/?s=Martin_Shkreli
http://best-big-deal.blogspot.com/search/?q=Martin_Shkreli
http://all-dba-support.blogspot.com/search/?q=Martin_Shkreli
http://mesothelioma-law-2016.blogspot.com/search/?q=Martin_Shkreli
http://data-recovery-professional2016.blogspot.com/search/?q=Martin_Shkreli
http://new2016info.blogspot.com/search/?q=Martin_Shkreli
http://my-support-oracle.blogspot.com/search/?q=Martin_Shkreli
http://annonces-utiles-2016.blogspot.fr/search/?q=Martin_Shkreli

http://blogspotseo2016.blogspot.com/search/?q=Martin_Shkreli
http://bestnews2o16.blogspot.com/search/?q=Martin_Shkreli
http://soft-pedia2010.blogspot.com/search/?q=Martin_Shkreli
http://greencard2010.blogspot.com/search/?q=Martin_Shkreli
http://gottabegossip.com/ex-pharma-ceo-martin-shkreli-sacks-his-legal-team-in-fraud-case/2f7b707b00000578-3369081-martin_shkreli-a-5_1450736728959/+%22Martin_Shkreli%22&hl=en&ct=clnk
http://www.emailsherlock.com/emailsearch/martin_shkreli%40turingpharma.com/&sa=U&ved=0ahUKEwjj6_jqwNLKAhWBKiwKHaQVCz4QFggeMAk&usg=AFQjCNHKpKzu4N7flKmKxq5D0bL31YRQdQ
http://anonresistance.com/d0xArchives/d0xxed/Martin_Shkreli.html&hl=en
http://www.youtube.com/results?hl=en&safe=off&q=%22Martin_Shkreli%22&gws_rd=cr&um=1&ie=UTF-8&gl=UA&sa=N&tab=w1
http://www.ottawacitizen.com/010716%2BTuring_Pharmaceuticals_Drug_Price%2BMartin_Shkreli/11637115/story.html&sa=U&ved=0ahUKEwjj6_jqwNLKAhWBKiwKHaQVCz4QFggcMAg&usg=AFQjCNGW7rpxBJgafgKc5gISJdd2fHDXMA
http://9gag.com/u/martin_shkreli&sa=U&ved=0ahUKEwjj6_jqwNLKAhWBKiwKHaQVCz4QFggZMAc&usg=AFQjCNEcTohTLlx5uJWdtwpB0vdjQMAwvQ
http://www.emailsherlock.com/emailsearch/martin_shkreli@turingpharma.com/&hl=en
http://gottabegossip.com/ex-pharma-ceo-martin-shkreli-sacks-his-legal-team-in-fraud-case/2f7b707b00000578-3369081-martin_shkreli-a-5_1450736728959/&sa=U&ved=0ahUKEwjj6_jqwNLKAhWBKiwKHaQVCz4QFggSMAQ&usg=AFQjCNHEUEjepB5lVH0VAPcT4PXzZnd8rA
http://anonresistance.com/d0xArchives/d0xxed/Martin_Shkreli.html+%22Martin_Shkreli%22&hl=en&ct=clnk
http://perezhilton.com/tag/martin_shkreli/&hl=en
http://www.startdays.com/?s=Martin_Shkreli
http://tax-los-angeles.blogspot.com/search/?q=Martin_Shkreli
http://facebook2010.blogspot.com/search/?q=Martin_Shkreli
http://h1n1-2010.blogspot.com/search/?q=Martin_Shkreli
http://orange-tunisie.blogspot.com/search/?q=Martin_Shkreli
http://debtadviceservice.blogspot.com/search/?q=Martin_Shkreli
http://austin-dwi-2010.blogspot.com/search/?q=Martin_Shkreli
http://lasts-tweets.blogspot.com/search/?q=Martin_Shkreli
http://socks4-proxy50.blogspot.com/search/?q=Martin_Shkreli
http://clickbankdot.blogspot.com/search/?q=Martin_Shkreli
http://startdays2016.blogspot.com/search/?q=Martin_Shkreli
http://topsclickbank.blogspot.com/search/?q=Martin_Shkreli
http://socks4-proxy-50.blogspot.com/search/?q=Martin_Shkreli

http://gottabegossip.com/ex-pharma-ceo-martin-shkreli-sacks-his-legal-team-in-fraud-case/2f7b707b00000578-3369081-martin_shkreli-a-5_1450736728959/+%22Martin_Shkreli%22&hl=en&ct=clnk
http://www.emailsherlock.com/emailsearch/martin_shkreli@turingpharma.com/+%22Martin_Shkreli%22&hl=en&ct=clnk
http://9gag.com/u/martin_shkreli&sa=U&ved=0ahUKEwjj6_jqwNLKAhWBKiwKHaQVCz4QFggZMAc&usg=AFQjCNEcTohTLlx5uJWdtwpB0vdjQMAwvQ
http://www.ottawacitizen.com/010716%2BTuring_Pharmaceuticals_Drug_Price%2BMartin_Shkreli/11637115/story.html&sa=U&ved=0ahUKEwjj6_jqwNLKAhWBKiwKHaQVCz4QFggcMAg&usg=AFQjCNGW7rpxBJgafgKc5gISJdd2fHDXMA
http://www.youtube.com/results?hl=en&safe=off&q=%22Martin_Shkreli%22&gws_rd=cr&um=1&ie=UTF-8&gl=UA&sa=N&tab=w1
http://perezhilton.com/tag/martin_shkreli/+%22Martin_Shkreli%22&hl=en&ct=clnk
http://softcam-keys.blogspot.com/search/?q=Martin_Shkreli
http://news-2010.blogspot.com/search/?q=Martin_Shkreli
http://journaldunet-2010.blogspot.com/search/?q=Martin_Shkreli
http://football-il.blogspot.com/search/?q=Martin_Shkreli
http://truman-support.blogspot.com/search/?q=Martin_Shkreli
http://welcome20016.blogspot.com/search/?q=Martin_Shkreli
http://tigretunisie.blogspot.com/search/?q=Martin_Shkreli
http://mosaiquefmnews.blogspot.com/search/?q=Martin_Shkreli
http://high-oracle.blogspot.com/search/?q=Martin_Shkreli
----------------------------------------------------
----------------------------------------------------

To view more updates, pictures, videos and other media files please visit and like our
Facebook Page: https://www.facebook.com/startdaysdontcom/
Twitter : https://twitter.com/startdaysdotcom
----------------------------------------
welcome to Best blogs
----------------------------------------
http://facebook2010.blogspot.com .::. http://bestnews2o16.blogspot.com/
http://soft-pedia2010.blogspot.com .::. http://journaldunet-2010.blogspot.com
http://lasts-tweets.blogspot.com .::. http://news-2010.blogspot.com
http://orange-tunisie.blogspot.com http://welcome20016.blogspot.com/
http://debtadviceservice.blogspot.com/ http://journaldunet-2010.blogspot.com/
http://tax-los-angeles.blogspot.com/ http://soft-pedia2010.blogspot.fr/
http://austin-dwi-2010.blogspot.com/ http://news-2010.blogspot.com/
http://h1n1-2010.blogspot.com/ http://journaldunet-2010.blogspot.com/
http://greencard2010.blogspot.com/ http://football-il.blogspot.com/
http://tigretunisie.blogspot.com/ http://truman-support.blogspot.com/
http://topsclickbank.blogspot.com/ http://softcam-keys.blogspot.com/
http://clickbankdot.blogspot.com/ http://truman-support.blogspot.com/
http://tigretunisie.blogspot.com/ http://tigretunisie.blogspot.com/
http://news-2010.blogspot.com/ http://bestnews2o16.blogspot.com/

Share This: Facebook Twitter Google+ Stumble Digg

vendredi 29 janvier 2016

Martin_Shkreli

By Unknown 16:14 No comments

Martin_Shkreli
Martin_Shkreli
Martin_Shkreli 2016-01-29
Martin_Shkreli 2016
Read more about Martin_Shkreli viste out website : http://www.startdays.com
All about ==> Martin_Shkreli viste out website : http://www.startdays.com
Martin_Shkreli update 2016-01-29 http://www.startdays.com
http://www.startdays.com
Martin Shkreli (born 1983) is an American entrepreneur and financial and pharmaceutical executive. He is co-founder of the hedge fund MSMB Capital Management, co-founder and former chief executive officer (CEO) of the biotechnology firm Retrophin LLC, and founder and former CEO of Turing Pharmaceuticals AG. In September 2015, Shkreli received widespread criticism when Turing obtained the manufacturing license for the antiparasitic drug Daraprim and raised its price by 5,556 percent (from US$13.50 to US$750 per tablet).
On December 17, 2015, Shkreli was arrested by the FBI on charges of securities fraud and released on bail. He resigned as CEO of Turing Pharmaceuticals and was replaced by the company's board chairman, Ron Tilles.

Early life and educationEdit
Martin Shkreli was born April 1, 1983, the son of Albanian and Croatian immigrants who worked as janitors. He, his two sisters, and his brother grew up in a working class community in Sheepshead Bay, Brooklyn,
Shkreli attended Hunter College High School. Shkreli eventually stopped attending classes and was asked to leave the school before his senior year, but received the credits necessary for his diploma through a program that placed him in an internship at the Wall Street hedge fund Cramer, Berkowitz and Company when he was 17. Sources are conflicted on whether Shkreli graduated from Hunter or whether he received sufficient credits there but actually graduated from City-As-School High School.
He went on to receive a bachelor's degree in business administration from New York's Baruch College in 2005. Shkreli told Vanity Fair that he developed an interest in chemistry when a family member suffered from treatment-resistant depression. In March 2015, Hunter College announced that Shkreli had donated $1,000,000 dollars to Hunter College High School. According to The New York Times, "At the time, Hunter officials hailed the gift, with the alumni associationâ€™s website declaring 'Martin Shkreli, from the Class of 2001, donates $1,000,000 to HCHS!' When asked this week whether Hunter was considering returning the money, a press officer declined to comment. Two members of the alumni association did not respond to emails. Several classmates say that when they heard about Mr. Shkreliâ€™s gift, they could not help but wonder whether it was meant as a sly act of one-upmanship." One of the classmates told The Times: â€œI thought it was weird since he hadn't graduated. It seemed almost
like a 'take that' move.â€

CareerEdit
During Shkreli's time at Cramer, Berkowitz and Company, he recommended short-selling (shorting) a biotech stock, believing that the companyâ€™s share price would drop. When it did so, Cramer's hedge fund profited. In 2003, Regeneron Pharmaceuticals was testing a weight loss drug, and Shkreli, at age 19, predicted that the stock price would fall. Shkreli's prediction drew the attention of the Securities and Exchange Commission, which investigated Shkreli's knowledge about the stock but found no wrongdoing on his part.

Hedge funds foundedEdit
After four years as an associate at Cramer Berkowitz, Shkreli worked as an analyst for Intrepid Capital Management and UBS Wealth Management. He then started his first hedge fund, Elea Capital Management, in 2006. In October 2007, Lehman Brothers won a $2.3 million default judgment against Shkreli and Elea, but collapsed before it could collect on the ruling.
In September 2009, Shkreli launched MSMB Capital Management, which took its name from the initials of the two founding portfolio managers, Shkreli and his childhood friend Marek Biestek. Shkreli and Biestek shorted biotech companies, then described flaws in the companies on stock trading chat rooms. Shkreli wrote on one investment site, â€œClinical data can be misleading, innocently biased, meaningless, manipulated and sometimes even downright doctored.â€
MSMB traded Orexigen Therapeutics stock in February 2011, around the time that its price plunged when the Food and Drug Administration (FDA) declined to approve the drug Contrave.
In 2011, Shkreli filed requests with the FDA to reject a new cancer diagnostic device from Navidea Biopharmaceuticals and an inhalable insulin therapy from MannKind Corporation while publicly short-selling both companies' stocks, the values of which dropped after Shkreli's interventions. The companies had difficulty launching the products as a result, although the FDA ultimately approved both.

RetrophinEdit
Shkreli founded Retrophin Inc. (NASDAQ: RTRX â€" the name is a portmanteau of "recombinant dystrophin") in 2011, and ran it as a portfolio company with an emphasis on biotechnology, to create treatments for rare diseases.
In 2011, MSMB made an unsolicited bid for AMAG Pharmaceuticals, US$378 million, and in September 2014, it acquired the rights to Thiola, a drug used to treat the rare disease cystinuria.
Retrophin's board decided to replace Shkreli in September 2014, and he resigned from the company the following month. He was replaced by Stephen Aselage. During Shkreli's tenure as CEO, the company's employees used alias Twitter accounts to make gangster rap jokes and encourage short selling of other biotech stocks. Critics argued that Shkreli was intelligent but too immature and unfocused for the job of CEO.
After Shkreli's departure, Retrophin filed a US$65 million lawsuit against him in August 2015, claiming that he had breached his duty of loyalty to the biopharmaceutical company in a long-running dispute over his use of company funds and "committed stock-trading irregularities and other violations of securities rules." The lawsuit alleged that Shkreli had threatened and harassed a former MSMB employee and his family. Shkreli and some of his business associates have been under criminal investigation by the U.S. Attorney for the Eastern District of New York since January 2015. Shkreli invoked his Fifth Amendment right against self-incrimination in order to avoid testifying during civil depositions.
Shkreli's name is on two patents held by Retrophin for drugs to treat PKAN.

Turing PharmaceuticalsEdit
Shkreli founded Turing Pharmaceuticals in February 2015, after his departure from Retrophin. He launched Turing with three drugs in development acquired from Retrophin: an intranasal version of ketamine for depression, an intranasal version of oxytocin, and Vecamyl for hypertension. Shkreli set a business strategy for Turing: to obtain licenses on out-of-patent medicines and reevaluate the pricing of each in pursuit of windfall profits for the new company, without the need to develop and bring its own drugs to market. As markets for out-of-patent drugs are often small, and obtaining regulatory approval to manufacture a generic version is expensive, Turing calculated that with closed distribution for the product and no competition, it could set high prices.

Price hike controversyEdit
In accordance with Shkreli's business plan, Turing acquired Daraprim (pyrimethamine) â€" an FDA-approved therapeutic since 1953 â€" for US$55 million on August 10, 2015, from Impax Laboratories.) The drug's most prominent use as of late 2015 was as an anti-malarial and an antiparasitic, in conjunction with leucovorin and a sulfonamide, to treat patients with toxoplasmosis, including in AIDS populations. The patent for Daraprim expired in 1953, and no generic version was available. The Turing-Impax deal included the condition that Impax remove the drug from regular wholesalers and pharmacies, so in June 2015, two months before the sale to Turing was announced, Impax switched to tightly controlled distribution. In keeping with its strategy for pricing in the face of limited competition (see above), Turing maintained the closed distribution.
On September 17, 2015, Dave Muoio of Healio, an in-depth clinical information website for health care specialists, reported on a letter from the Infectious Diseases Society of America and the HIV Medicine Association to executives at Turing, questioning a new pricing for Daraprim. The price of a dose of the drug in the U.S. market increased from US$13.50 to US$750 per pill, overnight, a 5451% increase.
The price increase was initially criticized, jointly, by the Infectious Diseases Society of America and the HIV Medicine Association, by the Pharmaceutical Research and Manufacturers of America, and soon thereafter by presidential candidates Hillary Clinton, Bernie Sanders, and Donald Trump. A subsequent organized effort called on Turing to return pricing to pre-September levels and to address several matters relating to the needs of patients, an effort that garnered endorsements from more than 160 medical specialty and patient-related organizations (as of early December 2015, 164 organizations from 31 states, the District of Columbia, and Puerto Rico).
In response to the controversy, the record label Collect Records publicly ended its business relationship with Shkreli, who had invested in the company.
In an interview with Bloomberg Markets, Shkreli claimed that despite the price increase, patient co-pays would actually be lower; that many patients would get the drug at no cost; that Turing has expanded its free drug program; and that it sold half of its drugs for one dollar. He defended the price hike by saying, "If there was a company that was selling an Aston Martin at the price of a bicycle, and we buy that company and we ask to charge Toyota prices, I don't think that that should be a crime." A few days later, Shkreli announced that he planned to lower the price by an unspecified amount, "in response to the anger that was felt by people." But in late November, Turing reversed course and said it would not lower the price after all. Following a request by Senator Bernie Sanders and Representative Elijah Cummings for details of Turing Pharmaceuticals' finances and price-setting practices in September 2015, the company hired four lobbyists from Buchanan, Ingersoll & Rooney with ba
ckgrounds in health care legislation and pharmaceutical pricing. In addition to the lobbyists, Shkreli hired a crisis public relations firm to help explain the pricing decision.
On October 22, 2015, Mark Baum, CEO of Imprimis Pharmaceuticals, announced that his company would provide a compounded (co-formulated) form of pyrimethamine, Daraprim's active agent, containing leucovorin, one of two drugs (alongside a sulfonamide) in the standard protocol to treat toxoplasmosis in AIDS and other populations.
Baum noted, "This is not the first time a sole supply generic drug â€" especially one that has been approved for use as long as Daraprim â€" has had its price increased suddenly and to a level that may make it unaffordable." He announced the availability of the compounded replacement for Daraprim as a part of a larger corporate program, "Imprimis Cares," to make "novel and customizable medicines available to physicians and patients... at accessible prices." Imprimis is now offering its compounded, orally taken formulations of pyrimethamine and leucovorin beginning at US$99 for a 100-count bottle, essentially a dollar a dose.
On November 23, 2015, Turing announced that the company would not reduce the list price of Daraprim, but said it planned instead to negotiate volume discounts of up to 50% for hospitals. Turing said it was not as important to cut the list price as to reduce the cost to hospitals, where most patients get their initial treatment. The company pledged that no patient needing Daraprim would ever be denied access. Infectious disease specialists and patient advocates, including Tim Horn of the Treatment Action Group and Carlos del Rio of the HIV Medicine Association, said Turing's actions were insufficient, given that patients initially treated for days at a hospital typically have to continue the treatment for weeks or months after leaving.

KaloBios PharmaceuticalsEdit
In November 2015, an investor group led by Shkreli acquired a majority stake in KaloBios Pharmaceuticals, Inc. (NASDAQ: KBIO), a biopharmaceutical company based in South San Francisco, California. Shkreli was named CEO of the company and also planned to continue in the role of CEO of Turing Pharmaceuticals. After his December 2015 arrest, KaloBios Pharmaceuticals terminated him as CEO. On 29 December KaloBios filed for Chapter 11 bankruptcy. This followed NASDAQ delistng its shares, and the resignation of two directors.

ArrestEdit
On December 17, 2015, Shkreli was arrested following a federal indictment by the FBI on securities fraud charges after an investigation into his tenure at MSMB Capital Management and Retrophin. He was accused of running a Ponzi-like scheme. A United States Department of Justice press release said, "As alleged, Martin Shkreli engaged in multiple schemes to ensnare investors through a web of lies and deceit." In an interview with the Wall Street Journal, Shkreli claimed that he was targeted by law enforcement for his price hikes of the drug Daraprim and his flamboyant personality. In his nationally syndicated column, political commentator Robert Reich suggested that what Shkreli "did wrong" was being more audacious while "playing the same game many others are playing on Wall Street".

Other projectsEdit
Shkreli is a League of Legends player who goes by the name "Imagine Cerebral" and began expressing interest in purchasing an eSports team in 2014. In May, Enemy eSports announced that it had rejected a US$1.2 million offer from Shkreli. Eventually, he founded his own team, Odyssey eSports, and aimed to qualify for the 2015 North American League of Legends Challenger Series. The team lost to Cloud9 Tempest in the qualifying tournament and failed to qualify. In August, Odyssey merged with Imagine, with Shkreli becoming chairman of the team. During the merger, the team acquired the Dota 2 team Leviathan.
In November 2015, Shkreli began livestreaming on YouTube showing him playing games such as League of Legends and chess, as well as offering financial advice. Shkreli had previously streamed on the website Twitch but switched to YouTube after his account was banned from Twitch for unknown reasons. Shkreli received a phone call from the FBI on the day of his arrest live while streaming. When Shkreli was arraigned in December and released on bail, he continued streaming from his apartment.
Shkreli had a contract with Collect Records and has offered to bail out Bobby Shmurda.

Personal lifeEdit

---------------------------------------
------ GOOGLE SEARCH ABOUT Martin_Shkreli UPDATE 2016-01-29
---------------------------------------

http://www.startdays.com/?s=Martin_Shkreli
http://best-big-deal.blogspot.com/search/?q=Martin_Shkreli
http://all-dba-support.blogspot.com/search/?q=Martin_Shkreli
http://mesothelioma-law-2016.blogspot.com/search/?q=Martin_Shkreli
http://data-recovery-professional2016.blogspot.com/search/?q=Martin_Shkreli
http://new2016info.blogspot.com/search/?q=Martin_Shkreli
http://my-support-oracle.blogspot.com/search/?q=Martin_Shkreli
http://annonces-utiles-2016.blogspot.fr/search/?q=Martin_Shkreli

http://blogspotseo2016.blogspot.com/search/?q=Martin_Shkreli
http://bestnews2o16.blogspot.com/search/?q=Martin_Shkreli
http://soft-pedia2010.blogspot.com/search/?q=Martin_Shkreli
http://greencard2010.blogspot.com/search/?q=Martin_Shkreli
http://www.emailsherlock.com/emailsearch/martin_shkreli@turingpharma.com/+%22Martin_Shkreli%22&hl=en&ct=clnk
http://perezhilton.com/tag/martin_shkreli/&hl=en
http://www.emailsherlock.com/emailsearch/martin_shkreli%40turingpharma.com/&sa=U&ved=0ahUKEwi_6eHuoNDKAhWjDpoKHTe5DnAQFggZMAc&usg=AFQjCNHKpKzu4N7flKmKxq5D0bL31YRQdQ
http://9gag.com/u/martin_shkreli&sa=U&ved=0ahUKEwi_6eHuoNDKAhWjDpoKHTe5DnAQFggXMAY&usg=AFQjCNEcTohTLlx5uJWdtwpB0vdjQMAwvQ
http://www.emailsherlock.com/emailsearch/martin_shkreli@turingpharma.com/&hl=en
http://www.funnyjunk.com/Wu%2Btang%2Bclan/text/5766554/2%23!&sa=U&ved=0ahUKEwi_6eHuoNDKAhWjDpoKHTe5DnAQFggeMAk&usg=AFQjCNGNzTq_j4v1UfnzJ3UkRP0tdVt-gg
http://anonresistance.com/d0xArchives/d0xxed/Martin_Shkreli.html&hl=en
http://perezhilton.com/tag/martin_shkreli/+%22Martin_Shkreli%22&hl=en&ct=clnk
http://henriettahudson.com/martin-shkreli-resigns-as-ceo-of-turing-pharmaceuticals/martin_shkreli-resignsx750/+%22Martin_Shkreli%22&hl=en&ct=clnk
http://www.youtube.com/results?hl=en&safe=off&q=%22Martin_Shkreli%22&gws_rd=cr&um=1&ie=UTF-8&gl=UA&sa=N&tab=w1
http://www.startdays.com/?s=Martin_Shkreli
http://tax-los-angeles.blogspot.com/search/?q=Martin_Shkreli
http://facebook2010.blogspot.com/search/?q=Martin_Shkreli
http://h1n1-2010.blogspot.com/search/?q=Martin_Shkreli
http://orange-tunisie.blogspot.com/search/?q=Martin_Shkreli
http://debtadviceservice.blogspot.com/search/?q=Martin_Shkreli
http://austin-dwi-2010.blogspot.com/search/?q=Martin_Shkreli
http://lasts-tweets.blogspot.com/search/?q=Martin_Shkreli
http://socks4-proxy50.blogspot.com/search/?q=Martin_Shkreli
http://clickbankdot.blogspot.com/search/?q=Martin_Shkreli
http://startdays2016.blogspot.com/search/?q=Martin_Shkreli
http://topsclickbank.blogspot.com/search/?q=Martin_Shkreli
http://socks4-proxy-50.blogspot.com/search/?q=Martin_Shkreli

http://www.youtube.com/results?hl=en&safe=off&q=%22Martin_Shkreli%22&gws_rd=cr&um=1&ie=UTF-8&gl=UA&sa=N&tab=w1
http://9gag.com/u/martin_shkreli&sa=U&ved=0ahUKEwi_6eHuoNDKAhWjDpoKHTe5DnAQFggXMAY&usg=AFQjCNEcTohTLlx5uJWdtwpB0vdjQMAwvQ
http://perezhilton.com/tag/martin_shkreli/&hl=en
http://henriettahudson.com/martin-shkreli-resigns-as-ceo-of-turing-pharmaceuticals/martin_shkreli-resignsx750/&hl=en
http://perezhilton.com/tag/martin_shkreli/+%22Martin_Shkreli%22&hl=en&ct=clnk
http://www.ottawacitizen.com/010716%2BTuring_Pharmaceuticals_Drug_Price%2BMartin_Shkreli/11637115/story.html&sa=U&ved=0ahUKEwi_6eHuoNDKAhWjDpoKHTe5DnAQFggVMAU&usg=AFQjCNGW7rpxBJgafgKc5gISJdd2fHDXMA
http://softcam-keys.blogspot.com/search/?q=Martin_Shkreli
http://news-2010.blogspot.com/search/?q=Martin_Shkreli
http://journaldunet-2010.blogspot.com/search/?q=Martin_Shkreli
http://football-il.blogspot.com/search/?q=Martin_Shkreli
http://truman-support.blogspot.com/search/?q=Martin_Shkreli
http://welcome20016.blogspot.com/search/?q=Martin_Shkreli
http://tigretunisie.blogspot.com/search/?q=Martin_Shkreli
http://mosaiquefmnews.blogspot.com/search/?q=Martin_Shkreli
http://high-oracle.blogspot.com/search/?q=Martin_Shkreli
----------------------------------------------------
----------------------------------------------------

To view more updates, pictures, videos and other media files please visit and like our
Facebook Page: https://www.facebook.com/startdaysdontcom/
Twitter : https://twitter.com/startdaysdotcom
----------------------------------------
welcome to Best blogs
----------------------------------------
http://facebook2010.blogspot.com .::. http://bestnews2o16.blogspot.com/
http://soft-pedia2010.blogspot.com .::. http://journaldunet-2010.blogspot.com
http://lasts-tweets.blogspot.com .::. http://news-2010.blogspot.com
http://orange-tunisie.blogspot.com http://welcome20016.blogspot.com/
http://debtadviceservice.blogspot.com/ http://journaldunet-2010.blogspot.com/
http://tax-los-angeles.blogspot.com/ http://soft-pedia2010.blogspot.fr/
http://austin-dwi-2010.blogspot.com/ http://news-2010.blogspot.com/
http://h1n1-2010.blogspot.com/ http://journaldunet-2010.blogspot.com/
http://greencard2010.blogspot.com/ http://football-il.blogspot.com/
http://tigretunisie.blogspot.com/ http://truman-support.blogspot.com/
http://topsclickbank.blogspot.com/ http://softcam-keys.blogspot.com/
http://clickbankdot.blogspot.com/ http://truman-support.blogspot.com/
http://tigretunisie.blogspot.com/ http://tigretunisie.blogspot.com/
http://news-2010.blogspot.com/ http://bestnews2o16.blogspot.com/

Share This: Facebook Twitter Google+ Stumble Digg

Martin_Shkreli

By Unknown 03:46 No comments

Martin_Shkreli
Martin_Shkreli
Martin_Shkreli 2016-01-29
Martin_Shkreli 2016
Read more about Martin_Shkreli viste out website : http://www.startdays.com
All about ==> Martin_Shkreli viste out website : http://www.startdays.com
Martin_Shkreli update 2016-01-29 http://www.startdays.com
http://www.startdays.com
Martin Shkreli (born 1983) is an American entrepreneur and financial and pharmaceutical executive. He is co-founder of the hedge fund MSMB Capital Management, co-founder and former chief executive officer (CEO) of the biotechnology firm Retrophin LLC, and founder and former CEO of Turing Pharmaceuticals AG. In September 2015, Shkreli received widespread criticism when Turing obtained the manufacturing license for the antiparasitic drug Daraprim and raised its price by 5,556 percent (from US$13.50 to US$750 per tablet).
On December 17, 2015, Shkreli was arrested by the FBI on charges of securities fraud and released on bail. He resigned as CEO of Turing Pharmaceuticals and was replaced by the company's board chairman, Ron Tilles.

Early life and educationEdit
Martin Shkreli was born April 1, 1983, the son of Albanian and Croatian immigrants who worked as janitors. He, his two sisters, and his brother grew up in a working class community in Sheepshead Bay, Brooklyn,
Shkreli attended Hunter College High School. Shkreli eventually stopped attending classes and was asked to leave the school before his senior year, but received the credits necessary for his diploma through a program that placed him in an internship at the Wall Street hedge fund Cramer, Berkowitz and Company when he was 17. Sources are conflicted on whether Shkreli graduated from Hunter or whether he received sufficient credits there but actually graduated from City-As-School High School.
He went on to receive a bachelor's degree in business administration from New York's Baruch College in 2005. Shkreli told Vanity Fair that he developed an interest in chemistry when a family member suffered from treatment-resistant depression. In March 2015, Hunter College announced that Shkreli had donated $1,000,000 dollars to Hunter College High School. According to The New York Times, "At the time, Hunter officials hailed the gift, with the alumni associationâ€™s website declaring 'Martin Shkreli, from the Class of 2001, donates $1,000,000 to HCHS!' When asked this week whether Hunter was considering returning the money, a press officer declined to comment. Two members of the alumni association did not respond to emails. Several classmates say that when they heard about Mr. Shkreliâ€™s gift, they could not help but wonder whether it was meant as a sly act of one-upmanship." One of the classmates told The Times: â€œI thought it was weird since he hadn't graduated. It seemed almost
like a 'take that' move.â€

CareerEdit
During Shkreli's time at Cramer, Berkowitz and Company, he recommended short-selling (shorting) a biotech stock, believing that the companyâ€™s share price would drop. When it did so, Cramer's hedge fund profited. In 2003, Regeneron Pharmaceuticals was testing a weight loss drug, and Shkreli, at age 19, predicted that the stock price would fall. Shkreli's prediction drew the attention of the Securities and Exchange Commission, which investigated Shkreli's knowledge about the stock but found no wrongdoing on his part.

Hedge funds foundedEdit
After four years as an associate at Cramer Berkowitz, Shkreli worked as an analyst for Intrepid Capital Management and UBS Wealth Management. He then started his first hedge fund, Elea Capital Management, in 2006. In October 2007, Lehman Brothers won a $2.3 million default judgment against Shkreli and Elea, but collapsed before it could collect on the ruling.
In September 2009, Shkreli launched MSMB Capital Management, which took its name from the initials of the two founding portfolio managers, Shkreli and his childhood friend Marek Biestek. Shkreli and Biestek shorted biotech companies, then described flaws in the companies on stock trading chat rooms. Shkreli wrote on one investment site, â€œClinical data can be misleading, innocently biased, meaningless, manipulated and sometimes even downright doctored.â€
MSMB traded Orexigen Therapeutics stock in February 2011, around the time that its price plunged when the Food and Drug Administration (FDA) declined to approve the drug Contrave.
In 2011, Shkreli filed requests with the FDA to reject a new cancer diagnostic device from Navidea Biopharmaceuticals and an inhalable insulin therapy from MannKind Corporation while publicly short-selling both companies' stocks, the values of which dropped after Shkreli's interventions. The companies had difficulty launching the products as a result, although the FDA ultimately approved both.

RetrophinEdit
Shkreli founded Retrophin Inc. (NASDAQ: RTRX â€" the name is a portmanteau of "recombinant dystrophin") in 2011, and ran it as a portfolio company with an emphasis on biotechnology, to create treatments for rare diseases.
In 2011, MSMB made an unsolicited bid for AMAG Pharmaceuticals, US$378 million, and in September 2014, it acquired the rights to Thiola, a drug used to treat the rare disease cystinuria.
Retrophin's board decided to replace Shkreli in September 2014, and he resigned from the company the following month. He was replaced by Stephen Aselage. During Shkreli's tenure as CEO, the company's employees used alias Twitter accounts to make gangster rap jokes and encourage short selling of other biotech stocks. Critics argued that Shkreli was intelligent but too immature and unfocused for the job of CEO.
After Shkreli's departure, Retrophin filed a US$65 million lawsuit against him in August 2015, claiming that he had breached his duty of loyalty to the biopharmaceutical company in a long-running dispute over his use of company funds and "committed stock-trading irregularities and other violations of securities rules." The lawsuit alleged that Shkreli had threatened and harassed a former MSMB employee and his family. Shkreli and some of his business associates have been under criminal investigation by the U.S. Attorney for the Eastern District of New York since January 2015. Shkreli invoked his Fifth Amendment right against self-incrimination in order to avoid testifying during civil depositions.
Shkreli's name is on two patents held by Retrophin for drugs to treat PKAN.

Turing PharmaceuticalsEdit
Shkreli founded Turing Pharmaceuticals in February 2015, after his departure from Retrophin. He launched Turing with three drugs in development acquired from Retrophin: an intranasal version of ketamine for depression, an intranasal version of oxytocin, and Vecamyl for hypertension. Shkreli set a business strategy for Turing: to obtain licenses on out-of-patent medicines and reevaluate the pricing of each in pursuit of windfall profits for the new company, without the need to develop and bring its own drugs to market. As markets for out-of-patent drugs are often small, and obtaining regulatory approval to manufacture a generic version is expensive, Turing calculated that with closed distribution for the product and no competition, it could set high prices.

Price hike controversyEdit
In accordance with Shkreli's business plan, Turing acquired Daraprim (pyrimethamine) â€" an FDA-approved therapeutic since 1953 â€" for US$55 million on August 10, 2015, from Impax Laboratories.) The drug's most prominent use as of late 2015 was as an anti-malarial and an antiparasitic, in conjunction with leucovorin and a sulfonamide, to treat patients with toxoplasmosis, including in AIDS populations. The patent for Daraprim expired in 1953, and no generic version was available. The Turing-Impax deal included the condition that Impax remove the drug from regular wholesalers and pharmacies, so in June 2015, two months before the sale to Turing was announced, Impax switched to tightly controlled distribution. In keeping with its strategy for pricing in the face of limited competition (see above), Turing maintained the closed distribution.
On September 17, 2015, Dave Muoio of Healio, an in-depth clinical information website for health care specialists, reported on a letter from the Infectious Diseases Society of America and the HIV Medicine Association to executives at Turing, questioning a new pricing for Daraprim. The price of a dose of the drug in the U.S. market increased from US$13.50 to US$750 per pill, overnight, a 5451% increase.
The price increase was initially criticized, jointly, by the Infectious Diseases Society of America and the HIV Medicine Association, by the Pharmaceutical Research and Manufacturers of America, and soon thereafter by presidential candidates Hillary Clinton, Bernie Sanders, and Donald Trump. A subsequent organized effort called on Turing to return pricing to pre-September levels and to address several matters relating to the needs of patients, an effort that garnered endorsements from more than 160 medical specialty and patient-related organizations (as of early December 2015, 164 organizations from 31 states, the District of Columbia, and Puerto Rico).
In response to the controversy, the record label Collect Records publicly ended its business relationship with Shkreli, who had invested in the company.
In an interview with Bloomberg Markets, Shkreli claimed that despite the price increase, patient co-pays would actually be lower; that many patients would get the drug at no cost; that Turing has expanded its free drug program; and that it sold half of its drugs for one dollar. He defended the price hike by saying, "If there was a company that was selling an Aston Martin at the price of a bicycle, and we buy that company and we ask to charge Toyota prices, I don't think that that should be a crime." A few days later, Shkreli announced that he planned to lower the price by an unspecified amount, "in response to the anger that was felt by people." But in late November, Turing reversed course and said it would not lower the price after all. Following a request by Senator Bernie Sanders and Representative Elijah Cummings for details of Turing Pharmaceuticals' finances and price-setting practices in September 2015, the company hired four lobbyists from Buchanan, Ingersoll & Rooney with ba
ckgrounds in health care legislation and pharmaceutical pricing. In addition to the lobbyists, Shkreli hired a crisis public relations firm to help explain the pricing decision.
On October 22, 2015, Mark Baum, CEO of Imprimis Pharmaceuticals, announced that his company would provide a compounded (co-formulated) form of pyrimethamine, Daraprim's active agent, containing leucovorin, one of two drugs (alongside a sulfonamide) in the standard protocol to treat toxoplasmosis in AIDS and other populations.
Baum noted, "This is not the first time a sole supply generic drug â€" especially one that has been approved for use as long as Daraprim â€" has had its price increased suddenly and to a level that may make it unaffordable." He announced the availability of the compounded replacement for Daraprim as a part of a larger corporate program, "Imprimis Cares," to make "novel and customizable medicines available to physicians and patients... at accessible prices." Imprimis is now offering its compounded, orally taken formulations of pyrimethamine and leucovorin beginning at US$99 for a 100-count bottle, essentially a dollar a dose.
On November 23, 2015, Turing announced that the company would not reduce the list price of Daraprim, but said it planned instead to negotiate volume discounts of up to 50% for hospitals. Turing said it was not as important to cut the list price as to reduce the cost to hospitals, where most patients get their initial treatment. The company pledged that no patient needing Daraprim would ever be denied access. Infectious disease specialists and patient advocates, including Tim Horn of the Treatment Action Group and Carlos del Rio of the HIV Medicine Association, said Turing's actions were insufficient, given that patients initially treated for days at a hospital typically have to continue the treatment for weeks or months after leaving.

KaloBios PharmaceuticalsEdit
In November 2015, an investor group led by Shkreli acquired a majority stake in KaloBios Pharmaceuticals, Inc. (NASDAQ: KBIO), a biopharmaceutical company based in South San Francisco, California. Shkreli was named CEO of the company and also planned to continue in the role of CEO of Turing Pharmaceuticals. After his December 2015 arrest, KaloBios Pharmaceuticals terminated him as CEO. On 29 December KaloBios filed for Chapter 11 bankruptcy. This followed NASDAQ delistng its shares, and the resignation of two directors.

ArrestEdit
On December 17, 2015, Shkreli was arrested following a federal indictment by the FBI on securities fraud charges after an investigation into his tenure at MSMB Capital Management and Retrophin. He was accused of running a Ponzi-like scheme. A United States Department of Justice press release said, "As alleged, Martin Shkreli engaged in multiple schemes to ensnare investors through a web of lies and deceit." In an interview with the Wall Street Journal, Shkreli claimed that he was targeted by law enforcement for his price hikes of the drug Daraprim and his flamboyant personality. In his nationally syndicated column, political commentator Robert Reich suggested that what Shkreli "did wrong" was being more audacious while "playing the same game many others are playing on Wall Street".

Other projectsEdit
Shkreli is a League of Legends player who goes by the name "Imagine Cerebral" and began expressing interest in purchasing an eSports team in 2014. In May, Enemy eSports announced that it had rejected a US$1.2 million offer from Shkreli. Eventually, he founded his own team, Odyssey eSports, and aimed to qualify for the 2015 North American League of Legends Challenger Series. The team lost to Cloud9 Tempest in the qualifying tournament and failed to qualify. In August, Odyssey merged with Imagine, with Shkreli becoming chairman of the team. During the merger, the team acquired the Dota 2 team Leviathan.
In November 2015, Shkreli began livestreaming on YouTube showing him playing games such as League of Legends and chess, as well as offering financial advice. Shkreli had previously streamed on the website Twitch but switched to YouTube after his account was banned from Twitch for unknown reasons. Shkreli received a phone call from the FBI on the day of his arrest live while streaming. When Shkreli was arraigned in December and released on bail, he continued streaming from his apartment.
Shkreli had a contract with Collect Records and has offered to bail out Bobby Shmurda.

Personal lifeEdit

---------------------------------------
------ GOOGLE SEARCH ABOUT Martin_Shkreli UPDATE 2016-01-29
---------------------------------------

http://www.startdays.com/?s=Martin_Shkreli
http://best-big-deal.blogspot.com/search/?q=Martin_Shkreli
http://all-dba-support.blogspot.com/search/?q=Martin_Shkreli
http://mesothelioma-law-2016.blogspot.com/search/?q=Martin_Shkreli
http://data-recovery-professional2016.blogspot.com/search/?q=Martin_Shkreli
http://new2016info.blogspot.com/search/?q=Martin_Shkreli
http://my-support-oracle.blogspot.com/search/?q=Martin_Shkreli
http://annonces-utiles-2016.blogspot.fr/search/?q=Martin_Shkreli

http://blogspotseo2016.blogspot.com/search/?q=Martin_Shkreli
http://bestnews2o16.blogspot.com/search/?q=Martin_Shkreli
http://soft-pedia2010.blogspot.com/search/?q=Martin_Shkreli
http://greencard2010.blogspot.com/search/?q=Martin_Shkreli
http://www.ottawacitizen.com/010716%2BTuring_Pharmaceuticals_Drug_Price%2BMartin_Shkreli/11637115/story.html&sa=U&ved=0ahUKEwixpZ3Q-c7KAhVD6CwKHa9LD4QQFggaMAc&usg=AFQjCNGW7rpxBJgafgKc5gISJdd2fHDXMA
http://perezhilton.com/tag/martin_shkreli/&hl=en
http://9gag.com/u/martin_shkreli&hl=en
http://henriettahudson.com/martin-shkreli-resigns-as-ceo-of-turing-pharmaceuticals/martin_shkreli-resignsx750/+%22Martin_Shkreli%22&hl=en&ct=clnk
http://www.youtube.com/results?hl=en&safe=off&q=%22Martin_Shkreli%22&gws_rd=cr&um=1&ie=UTF-8&gl=UA&sa=N&tab=w1
http://9gag.com/u/martin_shkreli&sa=U&ved=0ahUKEwixpZ3Q-c7KAhVD6CwKHa9LD4QQFggXMAY&usg=AFQjCNEcTohTLlx5uJWdtwpB0vdjQMAwvQ
http://henriettahudson.com/martin-shkreli-resigns-as-ceo-of-turing-pharmaceuticals/martin_shkreli-resignsx750/&sa=U&ved=0ahUKEwixpZ3Q-c7KAhVD6CwKHa9LD4QQFggcMAg&usg=AFQjCNGi9SspluXsLX6LT1ClWcY6T4BBKw
http://www.funnyjunk.com/Wu+tang+clan/text/5766554/2&hl=en
http://perezhilton.com/tag/martin_shkreli/&sa=U&ved=0ahUKEwixpZ3Q-c7KAhVD6CwKHa9LD4QQFggVMAU&usg=AFQjCNG9KRDHlOPQ73IkgNzqp9-b7UZvwg
http://henriettahudson.com/martin-shkreli-resigns-as-ceo-of-turing-pharmaceuticals/martin_shkreli-resignsx750/&hl=en
http://www.startdays.com/?s=Martin_Shkreli
http://tax-los-angeles.blogspot.com/search/?q=Martin_Shkreli
http://facebook2010.blogspot.com/search/?q=Martin_Shkreli
http://h1n1-2010.blogspot.com/search/?q=Martin_Shkreli
http://orange-tunisie.blogspot.com/search/?q=Martin_Shkreli
http://debtadviceservice.blogspot.com/search/?q=Martin_Shkreli
http://austin-dwi-2010.blogspot.com/search/?q=Martin_Shkreli
http://lasts-tweets.blogspot.com/search/?q=Martin_Shkreli
http://socks4-proxy50.blogspot.com/search/?q=Martin_Shkreli
http://clickbankdot.blogspot.com/search/?q=Martin_Shkreli
http://startdays2016.blogspot.com/search/?q=Martin_Shkreli
http://topsclickbank.blogspot.com/search/?q=Martin_Shkreli
http://socks4-proxy-50.blogspot.com/search/?q=Martin_Shkreli

http://www.youtube.com/results?hl=en&safe=off&q=%22Martin_Shkreli%22&gws_rd=cr&um=1&ie=UTF-8&gl=UA&sa=N&tab=w1
http://perezhilton.com/tag/martin_shkreli/&hl=en
http://9gag.com/u/martin_shkreli&sa=U&ved=0ahUKEwixpZ3Q-c7KAhVD6CwKHa9LD4QQFggXMAY&usg=AFQjCNEcTohTLlx5uJWdtwpB0vdjQMAwvQ
http://www.ottawacitizen.com/010716+Turing_Pharmaceuticals_Drug_Price+Martin_Shkreli/11637115/story.html&hl=en
http://henriettahudson.com/martin-shkreli-resigns-as-ceo-of-turing-pharmaceuticals/martin_shkreli-resignsx750/&sa=U&ved=0ahUKEwixpZ3Q-c7KAhVD6CwKHa9LD4QQFggcMAg&usg=AFQjCNGi9SspluXsLX6LT1ClWcY6T4BBKw
http://www.funnyjunk.com/Wu%2Btang%2Bclan/text/5766554/2&sa=U&ved=0ahUKEwixpZ3Q-c7KAhVD6CwKHa9LD4QQFggfMAk&usg=AFQjCNE5PpegzV4wKpyb6DC_PrXy81HLew
http://softcam-keys.blogspot.com/search/?q=Martin_Shkreli
http://news-2010.blogspot.com/search/?q=Martin_Shkreli
http://journaldunet-2010.blogspot.com/search/?q=Martin_Shkreli
http://football-il.blogspot.com/search/?q=Martin_Shkreli
http://truman-support.blogspot.com/search/?q=Martin_Shkreli
http://welcome20016.blogspot.com/search/?q=Martin_Shkreli
http://tigretunisie.blogspot.com/search/?q=Martin_Shkreli
http://mosaiquefmnews.blogspot.com/search/?q=Martin_Shkreli
http://high-oracle.blogspot.com/search/?q=Martin_Shkreli
----------------------------------------------------
----------------------------------------------------

To view more updates, pictures, videos and other media files please visit and like our
Facebook Page: https://www.facebook.com/startdaysdontcom/
Twitter : https://twitter.com/startdaysdotcom
----------------------------------------
welcome to Best blogs
----------------------------------------
http://facebook2010.blogspot.com .::. http://bestnews2o16.blogspot.com/
http://soft-pedia2010.blogspot.com .::. http://journaldunet-2010.blogspot.com
http://lasts-tweets.blogspot.com .::. http://news-2010.blogspot.com
http://orange-tunisie.blogspot.com http://welcome20016.blogspot.com/
http://debtadviceservice.blogspot.com/ http://journaldunet-2010.blogspot.com/
http://tax-los-angeles.blogspot.com/ http://soft-pedia2010.blogspot.fr/
http://austin-dwi-2010.blogspot.com/ http://news-2010.blogspot.com/
http://h1n1-2010.blogspot.com/ http://journaldunet-2010.blogspot.com/
http://greencard2010.blogspot.com/ http://football-il.blogspot.com/
http://tigretunisie.blogspot.com/ http://truman-support.blogspot.com/
http://topsclickbank.blogspot.com/ http://softcam-keys.blogspot.com/
http://clickbankdot.blogspot.com/ http://truman-support.blogspot.com/
http://tigretunisie.blogspot.com/ http://tigretunisie.blogspot.com/
http://news-2010.blogspot.com/ http://bestnews2o16.blogspot.com/

Share This: Facebook Twitter Google+ Stumble Digg

mardi 16 février 2016

Tori_Kelly

By Unknown 01:39 No comments

Tori_Kelly
Tori_Kelly
Tori_Kelly 2016-02-16
Tori_Kelly 2016
Read more about Tori_Kelly viste out website : http://www.startdays.com
All about ==> Tori_Kelly viste out website : http://www.startdays.com
Tori_Kelly update 2016-02-16 http://www.startdays.com
http://www.startdays.com
' probation, complete twelve weeks of anger management, and five days of community service in what the district attorney termed a negotiated settlement. Since then, he has permanently moved to Beverly Hills, California after the incident.
On August 13, 2014, the January DUI case was settled with a plea bargain pleading guilty to resisting an officer without violence, and a lesser charge of driving without due care and attention. He has been fined with US$500 and sentenced to attend both a 12-hour anger management course, and a program that teaches about the impact of drunken driving on victims. As part of the plea bargain, he has made a US$50,000 contribution to Our Kids, a local children's charity.

On September 1, 2014, Bieber was arrested and charged with assault and dangerous driving near his hometown of Stratford, Ontario after a collision between a minivan and Bieber's all-terrain vehicle on August 29. Ontario police said that he then "engaged in a physical altercation" with an occupant of the minivan. He was released shortly and his lawyer blamed the incident on "the unwelcome presence of paparazzi". On September 8, Toronto dropped an assault charge against him originally brought up on January 29 for an incident with a limousine driver in December 2013. In November 2014, he was ordered to appear in Argentina within 60 days by a Buenos Aires court to give testimony on an alleged assault on a photographer on November 9, 2013. When he failed to do so, an arrest warrant was issued and two of his bodyguards were released in Argentina in April 2015.

Racial epithet in videos
In June 2014, a video emerged of a 15-year-old Bieber telling a joke about black people, which used the word nigger multiple times. In the same month, a second video showed a 14-year-old Bieber giggling as he croons his song "One Less Lonely Girl", but parodying the main lyric as "One less lonely nigger", and stating that if he were to kill one, he'd be "part of the KKK". He apologized the day the latter was released: "Facing my mistakes from years ago has been one of the hardest things I've ever dealt with."

Filmography

Film and television

Guest appearances

Discography

My World 2.0 (2010)
Under the Mistletoe (2011)
Believe (2012)
Purpose (2015)

Tours
Urban Behavior Tour (2009)
My World Tour (2010â€"11)
Believe Tour (2012â€"13)
Purpose World Tour (2016)

See also
Justin Bibis
List of awards and nominations received by Justin Bieber
List of Billboard Social 50 number-one artists

References

Further reading

External links
Justin Bieber â€" official site
Justin Bieber discography at Discogs
Justin Bieber at DMOZ
Justin Bieber at the Internet Movie Database

title and url for this wikipedia site
Justin Bieber
https://en.wikipedia.org/wiki/Justin_Bieber
-------------------

all images related to this search
http://en.wikipedia.org/wiki/File:Believe_Tour_12,_2012.jpg
http://en.wikipedia.org/wiki/File:Believe_Tour_13,_2012.jpg
http://en.wikipedia.org/wiki/File:Commons-logo.svg
http://en.wikipedia.org/wiki/File:Folder_Hexagonal_Icon.svg
http://en.wikipedia.org/wiki/File:Justin_Bieber_2010.jpg
http://en.wikipedia.org/wiki/File:Justin_Bieber_2011_2.jpg
http://en.wikipedia.org/wiki/File:Justin_Bieber_Hallenstadion_Zurich_Switzerland.jpg
http://en.wikipedia.org/wiki/File:Justin_Bieber_NRJ_Music_Awards_2012.jpg
http://en.wikipedia.org/wiki/File:Justin_Bieber_mugshot,_front.jpg
------------------

you may also be interested in the following links
orry,couldn't find any links
Victoria Loren "Tori" Kelly (born December 14, 1992) is an American singer and songwriter who slowly gained recognition after starting to post videos on YouTube at the age of 14. When she was 16, Kelly auditioned for the singing competition television series American Idol. After being eliminated from the show, Kelly began to work on her own music. In 2012, she independently released her first EP that she produced, wrote, and mixed herself, titled Handmade Songs By Tori Kelly. The following year, Scooter Braun became her manager after seeing her videos on YouTube and introduced her to Capitol Records, with whom she signed in September. Kelly's second EP Foreword came out in October 2013 as her first major label release. On June 23, 2015, Kelly's debut album, Unbreakable Smile, was released. The lead single, "Nobody Love", was released in the spring and became her first US Billboard Hot 100 appearance. Kelly was nominated for Best New Artist at the 58th Grammy Awards.

Life and career
Kelly was born in Wildomar, California. Her father is Jamaican and half Puerto Rican, while her mother is of Irish and German descent. Growing up, she was exposed to a variety of music by her parents. "I give them a lot of credit for just playing all different genres, and no genre was off limits," she said when asked about her upbringing. Kelly has appeared on the show Star Search. With vocalist Tiffany Evans winning the title of Junior Champion in the junior singer division, she did not win the contest.
In 2004 she participated on America's Most Talented Kids, singing Christina Aguilera's "Keep on Singin' My Song" and won, beating out musician Hunter Hayes. She made a second appearance on the show in the Tournament of Champions, but lost to Antonio Pontarelli, a rock musician. At the age of twelve, Kelly was offered a record deal with Geffen Records, which she accepted, but because of conflicting ideas it was mutually agreed for her to be released. In 2007, Kelly began posting videos to YouTube, at the age of 14. The first video she uploaded was a cover of John Wesley Work, Jr.'s "Go Tell It On The Mountain", which she originally performed, back in December 2004. Kelly gained recognition for her acoustic cover, with a fellow YouTuber, named Angie Girl of Frank Ocean's "Thinkin Bout You".

2010â€"13: Handmade Songs by Tori Kelly
In 2010, Tori Kelly auditioned for Season 9 of American Idol in Denver, Colorado and made it through to Hollywood week but did not reach/make it to the "Top 24" of the artists. She had claimed that 'she was devastated' but she had 'given it her all'. She immediately began writing more songs and was asked to take part in a youth version of the 1985 charity song "We Are the World" titled "We Are the World: The Next Generation". On May 1, 2012, she released her first EP, titled Handmade Songs by Tori Kelly, which contained six songs on her own label Toraay Records. Kelly wrote, produced, engineered, and recorded the EP by herself in her bedroom. When it was released on iTunes it made it to the Top 10 Pop Albums. She called the EP a "warm up" to a full-length album that is to come in the future. The EP has sold more than 14,000 copies and reached number nine on the US Heatseekers Albums chart".
In February 2013, Kelly released a single called "Fill a Heart", which she wrote for the "Child Hunger Ends Here" campaign by ConAgra Foods and Feeding America. The song was later performed by British boy band The Wanted on Dancing With the Stars. Starting in April 2013, Kelly performed at eight different venues across continental U.S. for her "Fill a Heart" tour, helping out at the cities' food banks during the day. She has performed in venues such as the Troubador and the Roxy in Los Angeles, the Gramercy Theater in New York and Bush Hall in London. She has also been featured in magazines such as Teen Vogue, Elle and Glamour.
During mid-2013, Kelly's newly assigned manager Scooter Braun introduced Kelly to the heads of Capitol Records. She had been "very skeptical" she said about signing with a major record label in fear that things would not work out in her favor as had happened earlier in her career. "I'd been burned before. But when I met those guys, I had never felt that way: They were fans and really got me." And on September 6, 2013 she was signed to Capitol Records.

2013â€"present: Foreword, Unbreakable Smile and "Hollow"
In September 2013, Kelly announced on The Today Show that her major label debut, a second EP, titled Foreword, would be released on October 22, 2013 on Capitol Records. The EP has sold more than 16,000 copies, debuting at number 16 on the US Billboard 200. Kelly was the sole supporting act to Ed Sheeran at Madison Square Garden on November 1, 2013 and supported Sam Smith on his In the Lonely Hour UK tour in October 2014.
Kelly wrote and recorded a song called "Silent" for The Giver: Music Collection, supporting the film adaptation (The Giver) of the novel The Giver, which was released on iTunes on August 5, 2014. On August 7, 2014, Kelly posted a live acoustic version of the song on her YouTube channel; which has over 2.6 million views as of October 2015. Kelly was featured on "Lullaby" by British rapper Professor Green, which was released in the United Kingdom on September 14, 2014. The song peaked at number four on the UK Singles Chart, thus providing Kelly with her first British top ten hit. Kelly was featured on the medley "Winter Wonderland"/"Don't Worry Be Happy" on Pentatonix's album That's Christmas to Me that was released in October 2014. On December 1, 2014 it was announced that Tori Kelly was one of MTV's Artist's To Watch. She privately performed two songs for MTV: "Funny" and "Dear No One"; both can be found on her Artist To Watch page. Her "Funny" performance was aired on MTV for severa
l weeks.
Throughout 2014, Kelly worked with Braun on her debut album in which she had contributions from Toby Gad, Max Martin, and Ed Sheeran. The lead single from the album, "Nobody Love", was released on February 8, 2015. It was written by Rickard Goransson, Max Martin, and Tori Kelly herself. The album, entitled Unbreakable Smile, was released on June 23, 2015, and debuted at number two on the Billboard 200. Kelly performed "Should've Been Us" at the 2015 MTV Video Music Awards.
"Hollow" was released on October 22, 2015 as the first single from the new edition of the album. In the same month, Kelly became the brand-ambassador of William Rast, the clothing line co-founded by Justin Timberlake. In late 2015, Kelly received a nomination for Best New Artist at the 58th Grammy Awards.

Discography

Unbreakable Smile (2015)

Tours
Fill a Heart Tour (2012)
Foreword Tour (2013)
Where I Belong Tour (2015)
Unbreakable Tour (2016)

Awards and nominations

---------------------------------------
------ GOOGLE SEARCH ABOUT Tori_Kelly UPDATE 2016-02-16
---------------------------------------

http://www.startdays.com/?s=Tori_Kelly
http://best-big-deal.blogspot.com/search/?q=Tori_Kelly
http://all-dba-support.blogspot.com/search/?q=Tori_Kelly
http://mesothelioma-law-2016.blogspot.com/search/?q=Tori_Kelly
http://data-recovery-professional2016.blogspot.com/search/?q=Tori_Kelly
http://new2016info.blogspot.com/search/?q=Tori_Kelly
http://my-support-oracle.blogspot.com/search/?q=Tori_Kelly
http://annonces-utiles-2016.blogspot.fr/search/?q=Tori_Kelly

http://blogspotseo2016.blogspot.com/search/?q=Tori_Kelly
http://bestnews2o16.blogspot.com/search/?q=Tori_Kelly
http://soft-pedia2010.blogspot.com/search/?q=Tori_Kelly
http://greencard2010.blogspot.com/search/?q=Tori_Kelly
http://www.pikore.com/tori_kelly.smiti+%22Tori_Kelly%22&hl=en&ct=clnk
http://www.pikore.com/tori_kelly.smiti&sa=U&ved=0ahUKEwjko47H__vKAhVJ1ywKHYQSAm8QFggXMAY&usg=AFQjCNGlAqVG5aLjgjFf52ogxThJpdYd5A
http://www.pikore.com/tori_kelly.smiti&hl=en
http://www.pikore.com/yassssss.tori_kelly&hl=en
http://youtube.wikia.com/wiki/Tori_Kelly&hl=en
http://www.youtube.com/results?hl=en&safe=off&q=%22Tori_Kelly%22&gws_rd=cr&um=1&ie=UTF-8&gl=UA&sa=N&tab=w1
http://websta.me/n/yassssss.tori_kelly&sa=U&ved=0ahUKEwjko47H__vKAhVJ1ywKHYQSAm8QFggPMAI&usg=AFQjCNEhNJm9-EfV4LPpgXMxL1F8uQdm4Q
http://websta.me/n/yassssss.tori_kelly&hl=en
http://youtube.wikia.com/wiki/Tori_Kelly&sa=U&ved=0ahUKEwjko47H__vKAhVJ1ywKHYQSAm8QFggbMAg&usg=AFQjCNF7I_tsEU7gm3ZpxAc_iv3I6_lhMQ
http://www.pikore.com/yassssss.tori_kelly&sa=U&ved=0ahUKEwjko47H__vKAhVJ1ywKHYQSAm8QFggZMAc&usg=AFQjCNFDMEpQ66mq8FiAcPmBm5az5wXBpw
http://www.startdays.com/?s=Tori_Kelly
http://tax-los-angeles.blogspot.com/search/?q=Tori_Kelly
http://facebook2010.blogspot.com/search/?q=Tori_Kelly
http://h1n1-2010.blogspot.com/search/?q=Tori_Kelly
http://orange-tunisie.blogspot.com/search/?q=Tori_Kelly
http://debtadviceservice.blogspot.com/search/?q=Tori_Kelly
http://austin-dwi-2010.blogspot.com/search/?q=Tori_Kelly
http://lasts-tweets.blogspot.com/search/?q=Tori_Kelly
http://socks4-proxy50.blogspot.com/search/?q=Tori_Kelly
http://clickbankdot.blogspot.com/search/?q=Tori_Kelly
http://startdays2016.blogspot.com/search/?q=Tori_Kelly
http://topsclickbank.blogspot.com/search/?q=Tori_Kelly
http://socks4-proxy-50.blogspot.com/search/?q=Tori_Kelly

http://www.pikore.com/yassssss.tori_kelly&hl=en
http://www.pikore.com/yassssss.tori_kelly&sa=U&ved=0ahUKEwjko47H__vKAhVJ1ywKHYQSAm8QFggZMAc&usg=AFQjCNFDMEpQ66mq8FiAcPmBm5az5wXBpw
http://websta.me/n/yassssss.tori_kelly&sa=U&ved=0ahUKEwjko47H__vKAhVJ1ywKHYQSAm8QFggPMAI&usg=AFQjCNEhNJm9-EfV4LPpgXMxL1F8uQdm4Q
http://youtube.wikia.com/wiki/Tori_Kelly&hl=en
http://www.pikore.com/tori_kelly.smiti&sa=U&ved=0ahUKEwjko47H__vKAhVJ1ywKHYQSAm8QFggXMAY&usg=AFQjCNGlAqVG5aLjgjFf52ogxThJpdYd5A
http://www.pikore.com/tori_kelly.smiti&hl=en
http://softcam-keys.blogspot.com/search/?q=Tori_Kelly
http://news-2010.blogspot.com/search/?q=Tori_Kelly
http://journaldunet-2010.blogspot.com/search/?q=Tori_Kelly
http://football-il.blogspot.com/search/?q=Tori_Kelly
http://truman-support.blogspot.com/search/?q=Tori_Kelly
http://welcome20016.blogspot.com/search/?q=Tori_Kelly
http://tigretunisie.blogspot.com/search/?q=Tori_Kelly
http://mosaiquefmnews.blogspot.com/search/?q=Tori_Kelly
http://high-oracle.blogspot.com/search/?q=Tori_Kelly
----------------------------------------------------
----------------------------------------------------

To view more updates, pictures, videos and other media files please visit and like our
Facebook Page: https://www.facebook.com/startdaysdontcom/
Twitter : https://twitter.com/startdaysdotcom
----------------------------------------
welcome to Best blogs
----------------------------------------
http://facebook2010.blogspot.com .::. http://bestnews2o16.blogspot.com/
http://soft-pedia2010.blogspot.com .::. http://journaldunet-2010.blogspot.com
http://lasts-tweets.blogspot.com .::. http://news-2010.blogspot.com
http://orange-tunisie.blogspot.com http://welcome20016.blogspot.com/
http://debtadviceservice.blogspot.com/ http://journaldunet-2010.blogspot.com/
http://tax-los-angeles.blogspot.com/ http://soft-pedia2010.blogspot.fr/
http://austin-dwi-2010.blogspot.com/ http://news-2010.blogspot.com/
http://h1n1-2010.blogspot.com/ http://journaldunet-2010.blogspot.com/
http://greencard2010.blogspot.com/ http://football-il.blogspot.com/
http://tigretunisie.blogspot.com/ http://truman-support.blogspot.com/
http://topsclickbank.blogspot.com/ http://softcam-keys.blogspot.com/
http://clickbankdot.blogspot.com/ http://truman-support.blogspot.com/
http://tigretunisie.blogspot.com/ http://tigretunisie.blogspot.com/
http://news-2010.blogspot.com/ http://bestnews2o16.blogspot.com/

Share This: Facebook Twitter Google+ Stumble Digg

socks4 proxy 50

mercredi 27 janvier 2016

Hunter Zolomon

samedi 30 janvier 2016

Martin_Shkreli

vendredi 29 janvier 2016

Martin_Shkreli

Martin_Shkreli

mardi 16 février 2016

Tori_Kelly

Popular Posts

Blog Archive